Cargando…

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608536/ https://www.ncbi.nlm.nih.gov/pubmed/36283739 http://dx.doi.org/10.1136/jitc-2021-004223corr1

Ejemplares similares

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
por: Naing, Aung, et al.
Publicado: (2022)

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
por: Luke, Jason J., et al.
Publicado: (2023)

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
por: Naing, Aung, et al.
Publicado: (2022)

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors
por: Beatty, Gregory L., et al.
Publicado: (2018)

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
por: Powderly, John D, et al.
Publicado: (2022)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020)

Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine
por: Tahaghoghi-Hajghorbani, Sahar, et al.
Publicado: (2023)

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
por: Mitchell, Tara C., et al.
Publicado: (2018)

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
por: Gangadhar, Tara C, et al.
Publicado: (2015)

Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Publicado: (2020)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)
por: Kadia, T., et al.
Publicado: (2022)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
por: Waqar, Saiama N., et al.
Publicado: (2022)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Correction: Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
Publicado: (2020)

Correction to: Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment
por: Sasidharan Nair, Varun, et al.
Publicado: (2021)

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Correction: Phosphorescence Monitoring of Hypoxic Microenvironment in Solid-Tumors to Evaluate Chemotherapeutic Effects Using the Hypoxia-Sensitive Iridium (III) Coordination Compound
Publicado: (2015)

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study
por: Fukuhara, Noriko, et al.
Publicado: (2022)

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Phase I study of pemetrexed with sorafenib in advanced solid tumors
por: Poklepovic, Andrew, et al.
Publicado: (2016)

Phase I study of camrelizumab in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Correction to: Using single-cell sequencing technology to detect circulating tumor cells in solid tumors
por: Xu, Jiasheng, et al.
Publicado: (2022)

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
por: Saleh, Mansoor N., et al.
Publicado: (2022)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
por: Werner, Theresa L., et al.
Publicado: (2018)

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
por: Cascone, T., et al.
Publicado: (2021)

A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft‐versus‐host disease
por: Pratta, Michael, et al.
Publicado: (2022)

Phase I study of olaratumab in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
por: Panfili, Eleonora, et al.
Publicado: (2023)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)
por: Hamadani, M., et al.
Publicado: (2022)

Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors
por: Johnson, Abigail, et al.
Publicado: (2022)

Correction to: Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma
por: Eckert, Alexander W., et al.
Publicado: (2018)

Correction: Th1(high) in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC
por: Jian, Huang, et al.
Publicado: (2017)

Correction: Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment
por: Li, Wen, et al.
Publicado: (2022)

Interplay between Solid Tumors and Tumor Microenvironment
por: Kim, Seung-Jin, et al.
Publicado: (2022)

Correction: MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment
por: Yuan, Hongyan, et al.
Publicado: (2018)

Correction: Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function
por: Dyck, Lydia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_218macb5t73a81cl8ltr7q3d5j